Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Colorado at Denver and Health Sciences Center |
---|---|
Information provided by: | University of Colorado at Denver and Health Sciences Center |
ClinicalTrials.gov Identifier: | NCT00792012 |
The purpose of the study is to find out the highest dose per fraction of hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) that can be safely given with temozolomide chemotherapy.
Hypo-IMRT is given in fewer treatments than conventional radiation therapy. This will be a dose per fraction escalation study. A dose per fraction escalation study means that successive groups of patients will receive higher doses per fraction of radiation while keeping the total dose of radiation the same (60 Gy, Gy is a radiation unit). The radiation dose per fraction will be increased and the numbers of radiation treatments will be decreased until a fraction dose is reached at which there are unacceptable side effect compared with possible benefit. Which group you are in will depend on what stage the study has reached at the time you decide to participate.
This research is being done because with current standard radiation therapy (A total dose of 60 Gy given 2 Gy a day over 6 weeks.) the outcome is very poor. New and more effective radiation therapy methods are desperately needed for the patients like you with GBM.
In this study, radiation therapy is given together with chemotherapy of Temozolomide.
This study is also designed to monitor the level of some of the known cytokines (specific proteins in the blood) before and after radiation, and in meantime to screen unknown proteins in patients' blood before and after radiation therapy. Hopefully, this will provide us with some clues for future study of monitoring radiation damage, and possibly new therapeutic approach for patients like you with GBM.
Condition | Intervention | Phase |
---|---|---|
Glioblastoma Multiforme |
Radiation: Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Drug: Temozomide |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment |
Official Title: | A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) |
Estimated Enrollment: | 27 |
Study Start Date: | November 2005 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Changhu Chen, MD | 720-848-0116 | changhu.chen@ucdenver.edu |
Contact: Monica Robischon, RN | 720-848-0661 | monica.robischon@ucdenver.edu |
United States, Colorado | |
University of Colorado Cancer Center | Recruiting |
Aurora, Colorado, United States, 80045 | |
Principal Investigator: Changhu Chen, MD |
Responsible Party: | University of Colorado Cancer Center ( Changhu Chen, MD ) |
Study ID Numbers: | 05-0562 |
Study First Received: | November 13, 2008 |
Last Updated: | November 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00792012 |
Health Authority: | United States: Institutional Review Board |
Neuroectodermal Tumors Glioblastoma Glioblastoma multiforme Astrocytoma Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Glioma Temozolomide Neoplasms, Glandular and Epithelial |
Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial |